VetMedGuide

Vet Med Guide

Older dog on a clinic mat with joint-mobility reference graphics.
Pharmaceuticals2026-05-21 · 14 min read

Dog Arthritis Treatment: NSAIDs, Librela, Adequan, and Multimodal Pain Management

A practical guide to canine osteoarthritis treatment — how veterinarians combine NSAIDs, Librela injections, Adequan, weight management, and physical therapy into a multimodal plan, and what the.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Osteoarthritis (OA) is one of the most common chronic pain conditions in dogs — and one of the most underdiagnosed. Studies have found radiographic evidence of OA in up to 40% of dogs as young as 8 months of age, yet clinical signs often go unrecognized until the disease is well advanced. Owners frequently attribute slowness to rise, reluctance to jump, decreased activity, and subtle gait changes to "just getting older" rather than to a treatable disease process.

OA is progressive, painful, and currently incurable. But it is manageable. The veterinary profession has moved decisively away from prescribing a single pain medication and hoping for the best. Three international guidelines — the 2022 AAHA Pain Management Guidelines, the 2022 WSAVA Guidelines for Recognition, Assessment, and Treatment of Pain, and the 2023 COAST (Canine Osteoarthritis Staging Tool) Development Group's international consensus — all recommend a multimodal approach: combining pharmacologic and non-pharmacologic treatments that target different pain pathways and aspects of joint degeneration.

This article explains what that multimodal approach looks like in practice, how the major drug classes work, what the evidence supports, and what to discuss with your veterinarian.

Why single-drug treatment is not enough

Canine OA involves the entire joint: cartilage degradation, synovitis (inflammation of the joint lining), subchondral bone sclerosis, periarticular muscle atrophy, and capsule fibrosis. Pain arises from multiple sources — inflamed synovium, exposed subchondral bone, stressed ligaments and tendons, and altered biomechanics. In roughly a quarter of affected dogs, OA pain also develops a neuropathic component, where the nervous system itself amplifies pain signals beyond what the tissue damage would predict.

No single drug addresses all of those pathways. NSAIDs reduce inflammation and prostaglandin-mediated pain but do not repair cartilage. Librela blocks nerve growth factor signaling but does not modify the disease process. Adequan targets cartilage metabolism but is not a primary analgesic. Weight management reduces mechanical loading and systemic inflammation but takes time.

The multimodal approach combines treatments so that each one can do what it does best — and often at lower individual doses than would be needed alone. That is the standard of care.

NSAIDs: the traditional cornerstone

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most predictably effective pharmacologic treatment for OA pain in dogs. They work by inhibiting cyclooxygenase (COX) enzymes, which convert arachidonic acid into prostaglandins — molecules that drive pain, inflammation, and fever. By reducing prostaglandin production at the joint, NSAIDs decrease both inflammation and pain sensitivity.

FDA-approved NSAIDs for canine OA

Several NSAIDs are labeled for OA in dogs:

  • Carprofen (Rimadyl) — the most widely prescribed veterinary NSAID
  • Meloxicam (Metacam) — commonly used worldwide; available as an oral liquid
  • Deracoxib (Deramaxx) — a COX-2 selective NSAID
  • Firocoxib (Previcox) — another COX-2 selective option
  • Robenacoxib (Onsior) — labeled for postoperative pain; used off-label for OA in some countries
  • Grapiprant (Galliprant) — technically a piprant, not a traditional NSAID (see below)

Grapiprant (Galliprant): a different mechanism

Grapiprant does not inhibit COX enzymes. Instead, it selectively blocks the EP4 receptor — the specific receptor through which prostaglandin E2 mediates its pain and inflammation effects. This means grapiprant spares many of the protective prostaglandins that maintain stomach lining integrity, kidney blood flow, and blood clotting. The FDA classifies it as an NSAID and carries the same class warnings, but some evidence suggests it may have fewer serious gastrointestinal and renal adverse events than traditional NSAIDs. It is worth noting that grapiprant has not been directly compared to carprofen or meloxicam in a large head-to-head trial for long-term OA management.

Common side effects and monitoring

The most common adverse events across all veterinary NSAIDs are:

  • Vomiting
  • Diarrhea
  • Decreased appetite or anorexia
  • Lethargy

More serious but less common events include gastrointestinal ulceration, kidney injury, and liver toxicity. This is why guidelines recommend baseline bloodwork (complete blood count, serum chemistry with liver and kidney values) before starting long-term NSAID therapy, and periodic rechecks during treatment. Dogs with pre-existing kidney disease, liver disease, or a history of GI ulcers may not be appropriate candidates for NSAIDs.

NSAIDs must not be combined with each other or with corticosteroids (such as prednisone or dexamethasone). A washout period — typically 3 to 7 days — is required when switching between NSAIDs. This decision should always be made by the prescribing veterinarian.

Librela (bedinvetmab): the newer option

Librela is a monoclonal antibody that targets nerve growth factor (NGF) — a protein elevated in arthritic joints that amplifies pain signaling. It is given as a once-monthly subcutaneous injection at the veterinary clinic. Because it is a protein (a fully canine antibody), it is degraded through normal protein breakdown pathways rather than being metabolized by the liver or kidneys. This gives it a different safety profile from oral NSAIDs.

Evidence for efficacy

In the U.S. field study for FDA approval, 47.4% of owners reported improvement in their dog's pain scores with Librela versus 36.6% with placebo. A 2025 randomized clinical trial published in Frontiers in Veterinary Science (Innes et al.) compared Librela to meloxicam in approximately 100 dogs with OA and found no significant difference in efficacy between the two treatments. Both improved pain scores, and the Librela group reported fewer adverse events.

What Librela does NOT do

Librela controls pain by blocking pain signals. It does not reduce inflammation in the way NSAIDs do, and it does not slow or reverse cartilage damage. It is a pain-management tool, not a disease-modifying one. The 2022 AAHA and WSAVA guidelines and the 2023 COAST consensus all position anti-NGF monoclonal antibodies as a first-line option for OA pain — alongside NSAIDs — but they are clear that Librela is one component of a broader plan, not a stand-alone therapy.

Side effects and post-marketing safety signals

Common side effects from clinical trials include injection site swelling, urinary tract infections, and bacterial skin infections. Post-marketing reports collected after launch have included ataxia, anorexia, lethargy, urinary incontinence, polydipsia (increased thirst), and seizures. The FDA completed a standard adverse event review in September 2024 and recommended that the label be updated to reflect these events.

In 2025, reports emerged of rapidly progressive osteoarthritis (RPOA) in some dogs receiving Librela. A case series published by Farrell et al. in Frontiers in Veterinary Science documented 19 dogs with suspected worsening of joint disease following Librela use, many of whom were also receiving concurrent NSAIDs. This mirrors a signal seen in human anti-NGF trials. Studies are underway at multiple universities to understand whether there is a causal relationship. Until more is known, the Canine Arthritis Resources and Education (CARE) group recommends: (1) avoiding concurrent NSAID use with Librela when possible, using alternative medications for breakthrough pain; (2) avoiding Librela in dogs with unstable joints or recent cruciate ligament rupture; and (3) controlling exercise after starting Librela, with focus on proprioception and strengthening exercises guided by a rehabilitation professional.

When Librela may not be appropriate

  • Dogs under 12 months of age (not labeled)
  • Breeding, pregnant, or lactating dogs (contraindicated)
  • Dogs with pre-existing neurologic disease (reports include neurologic events)
  • Dogs with unstable joints or recent cruciate ligament rupture (Librela is not indicated for non-OA musculoskeletal conditions)
  • Dogs where long-term concurrent NSAID use is anticipated (safety not established)

Adequan: the cartilage-targeting option

Adequan (polysulfated glycosaminoglycan, or PSGAG) is the only FDA-approved drug shown to slow or reverse the degenerative process in articular cartilage. It is not a pain medication in the traditional sense — it works by inhibiting degradative enzymes in the joint, stimulating synovial fluid production, and supporting cartilage repair.

How it is given

Adequan is labeled for intramuscular (IM) injection, twice weekly for up to 4 weeks (8 injections total). Many veterinarians administer it subcutaneously (SC) as an off-label route — pharmacokinetic studies have shown similar bioavailability via the SC route. After the loading series, some veterinarians continue maintenance injections at reduced frequency based on clinical response.

Where Adequan fits best

Because Adequan addresses the disease process in cartilage rather than just pain, it is most useful in early to moderate OA, where there is still cartilage to preserve. It is less effective in end-stage joints where cartilage is already gone. It can be combined with NSAIDs or Librela (given at a different injection site) as part of a multimodal plan.

Contraindications

Adequan should not be used in dogs with bleeding disorders (it can prolong clotting time), and caution is advised in dogs with significant renal or hepatic impairment. As with any injectable medication, monitor for signs of hypersensitivity.

Building a multimodal plan

The table below shows the major treatment components that guidelines and clinical evidence support for canine OA:

Component Examples What it targets
First-line pain control NSAIDs (carprofen, meloxicam, grapiprant) or Librela Prostaglandin-mediated inflammation and pain, or NGF-mediated pain signaling
Disease modification Adequan (PSGAG) Cartilage degradation; slows disease progression
Adjunct analgesics Amantadine, gabapentin, acetaminophen (dogs only, under veterinary supervision) Neuropathic pain component; central sensitization; multimodal pain relief
Weight management Caloric restriction, therapeutic weight-loss diet Mechanical loading, systemic inflammation from adipose tissue
Controlled exercise Leash walks, low-impact activity, swimming Muscle support, joint stability, endogenous pain relief
Physical rehabilitation Hydrotherapy, therapeutic laser, acupuncture, massage Pain modulation, range of motion, muscle strengthening
Environmental modifications Non-slip rugs, ramps, orthopedic bedding, raised bowls Reduced joint stress, fall prevention
Supplements Omega-3 fatty acids (EPA/DHA), undenatured type II collagen Anti-inflammatory effects; evidence variable for glucosamine/chondroitin

No single row in this table is sufficient on its own. The strength of the multimodal approach is in the combination.

What treatment by OA severity looks like

The COAST framework stages canine OA from 0 (clinically normal, no risk factors) to 4 (severe clinical signs). Treatment is guided by clinical signs, not just radiographs:

Early/mild OA (COAST Stage 2) — The foundation is non-pharmacologic: weight optimization to a lean body condition, controlled leash walks, omega-3 supplementation, and environmental modifications. Adequan may be started here to preserve cartilage. NSAIDs or Librela can be used if pain is present but may not be needed continuously.

Moderate OA (COAST Stage 3) — First-line pain medication becomes central. Either an NSAID or Librela is appropriate per guidelines, chosen based on the dog's health profile and owner preference. Weight management and exercise continue. Physical rehabilitation (hydrotherapy, therapeutic laser, acupuncture) is added. If pain is not fully controlled, adjunct medications like amantadine or gabapentin may be introduced.

Severe OA (COAST Stage 4) — Full multimodal therapy: NSAID or Librela plus amantadine (an NMDA-receptor antagonist for neuropathic pain) plus gabapentin (a calcium-channel modulator), combined with physical rehabilitation, aggressive weight management, environmental modifications (ramps, traction flooring, orthopedic bedding, assistive slings), and ongoing Adequan if cartilage preservation is still possible. Pain that remains uncontrolled at this stage warrants re-evaluation — including whether the diagnosis is correct and whether surgical intervention is needed.

Weight management: the most underrated treatment

Maintaining a lean body condition is the single most evidence-supported intervention for reducing OA progression in dogs. A landmark longitudinal study found that caloric restriction over a five-year period significantly reduced the development and severity of hip dysplasia and coxofemoral OA in dogs at risk.

Adipose tissue is the body's largest endocrine organ. It secretes proinflammatory cytokines and adipokines that drive both pain and joint degeneration — meaning excess weight contributes to OA through mechanical loading and systemic inflammation. Even modest weight loss in overweight dogs with OA produces measurable improvements in lameness and mobility.

Weight loss should be gradual and supervised by a veterinarian. Simply reducing the portion of a maintenance diet can cause malnutrition; a therapeutic weight-loss diet ensures adequate protein and micronutrients while restricting calories. The goal is a body condition score on the lean side of normal — what many owners perceive as "too thin" is often ideal for an arthritic dog.

What to ask your veterinarian

  • "Is my dog's pain actually from OA, or could it be something else?" Cranial cruciate ligament rupture, neurologic disease, bone tumors, and tick-borne infections can mimic or coexist with OA. A complete orthopedic and neurologic examination — and sometimes radiographs or additional diagnostics — is needed before committing to long-term OA medication.
  • "What bloodwork do we need before starting medication?" Baseline kidney and liver values are essential before NSAIDs. Bloodwork is also prudent before starting Librela, even though it is not processed by the liver or kidneys.
  • "How will we know if the treatment is working?" Validated owner questionnaires (the Canine Brief Pain Inventory, Liverpool Osteoarthritis in Dogs score) provide semi-objective tracking. Your veterinarian should establish baseline scores and recheck at defined intervals.
  • "What side effects should I watch for?" For NSAIDs: vomiting, diarrhea, dark or tarry stools, decreased appetite, increased thirst or urination. For Librela: stumbling, weakness, urinary incontinence, increased drinking, sudden changes in appetite or energy. Report any of these promptly.
  • "Can we combine treatments?" Ask specifically about whether your dog's plan includes weight management, physical rehabilitation, and environmental modifications — not just medication.

When surgery may be needed

OA in dogs is frequently secondary to an underlying structural problem: cranial cruciate ligament (CCL) rupture, hip dysplasia, elbow dysplasia, patellar luxation, or osteochondritis dissecans (OCD). When joint instability or malalignment is the driver, surgery to address the underlying problem is often necessary. Surgery does not "cure" OA — it addresses the instability that is accelerating it. OA management continues after surgery, often with the same multimodal approach described above.

Common surgical interventions include tibial plateau leveling osteotomy (TPLO) or lateral suture repair for CCL rupture, total hip replacement or femoral head ostectomy for hip dysplasia, and arthroscopy for elbow dysplasia fragments. The decision for surgery depends on the dog's age, the joint involved, the severity of instability, and the owner's goals and resources.

Key points

  • OA is a progressive disease of the entire joint. No single treatment addresses all pain pathways and disease mechanisms.
  • Three international guidelines (AAHA 2022, WSAVA 2022, COAST 2023) recommend a multimodal approach combining pharmacologic and non-pharmacologic therapies.
  • NSAIDs and Librela are both first-line options for OA pain. NSAIDs address inflammation; Librela addresses nerve growth factor-mediated pain. They work by different mechanisms and are not interchangeable.
  • Adequan is the only FDA-approved drug that slows cartilage degeneration. It is most useful in early to moderate OA.
  • Weight management to a lean body condition is the most evidence-supported intervention for reducing OA progression.
  • Every OA plan should include non-drug components: controlled exercise, physical rehabilitation, and environmental modifications.
  • Baseline bloodwork is needed before starting NSAIDs and is prudent before Librela. Discuss side-effect monitoring with your veterinarian.

Sources

Topics
Canine Osteoarthritis
Related Articles